Brevan Howard Capital Management LP Decreases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Brevan Howard Capital Management LP trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 15.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,068 shares of the medical research company's stock after selling 3,509 shares during the period. Brevan Howard Capital Management LP's holdings in IQVIA were worth $3,747,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Synergy Asset Management LLC purchased a new position in IQVIA in the fourth quarter valued at about $33,000. GKV Capital Management Co. Inc. bought a new stake in shares of IQVIA in the 4th quarter worth approximately $39,000. Lee Danner & Bass Inc. purchased a new position in IQVIA in the fourth quarter valued at approximately $44,000. Zions Bancorporation N.A. grew its holdings in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares during the period. Finally, Versant Capital Management Inc increased its position in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after buying an additional 93 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Stifel Nicolaus dropped their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. BTIG Research lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Robert W. Baird lowered their price target on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research report on Wednesday. StockNews.com downgraded shares of IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Finally, Morgan Stanley lifted their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $231.71.

IQVIA Price Performance

NYSE IQV traded down $4.39 on Friday, reaching $148.90. 1,677,229 shares of the company's stock traded hands, compared to its average volume of 1,468,618. The stock has a market cap of $25.76 billion, a PE ratio of 19.85, a P/E/G ratio of 1.99 and a beta of 1.34. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 12 month low of $135.97 and a 12 month high of $252.88. The stock has a 50-day simple moving average of $164.60 and a 200 day simple moving average of $189.07.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The business had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. During the same period in the prior year, the business posted $2.54 earnings per share. The company's revenue was up 2.5% on a year-over-year basis. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.